

ABBOTT RECEIVES FDA APPROVAL FOR TACTIFLEX™ ABLATION CATHETER FOR TREATMENT OF ABNORMAL HEART RHYTHM

- TactiFlex™ Ablation Catheter, Sensor Enabled™, is the world's first ablation catheter designed with a unique flexible electrode tip and contact force sensing to treat patients with atrial fibrillation
- When used with Abbott's EnSite™ X EP System, physicians have better visualization allowing for more accuracy and precision with the TactiFlex catheter, leading to reduced procedure times and better safety

ABBOTT PARK, Ill., May 19, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's [TactiFlex™ Ablation Catheter, Sensor Enabled™](#), the world's first ablation catheter with a flexible tip and contact force technology.

Used to perform an ablation procedure to treat atrial fibrillation (AFib), the most common abnormal heart rhythm, the TactiFlex catheter can result in reduced procedure times¹ and better safety when compared to the company's previous generation catheters².

More than 37 million people worldwide live with AFib³ and numbers are predicted to more than double by 2050.⁴ An additional five million⁵ cases are diagnosed every year, indicating a growing health challenge that demands innovative solutions for patients and their physicians.

"For those suffering from AFib, daily life can be challenging as people often feel dizziness, chest pain and heart palpitations. AFib can lead to stroke if left untreated, making it critical for physicians to treat the issue as early as possible," said Larry A. Chinitz, M.D., director of the Heart Rhythm Center and co-director of NYU Langone Heart in New York City. "We are entering the next chapter of AFib ablation with new tools such as Abbott's TactiFlex that, when used with mapping systems to accurately identify the source of an arrhythmia, can safely and efficiently treat the problem in ways we never thought possible a decade ago."

New Catheter Pairs with Abbott's Other Best-in-Class Solutions for AFib Patients

The TactiFlex catheter is designed to be used with Abbott's [EnSite X EP System](#), an industry-leading heart mapping system, which allows physicians to view and precisely identify areas in the heart that require ablation.

Unlike other catheters on the market, the TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall. This helps direct fluid to the treated tissue¹ and allows for more accurate positioning of the catheter – providing up to two-times higher stability in a beating heart – for consistent therapy delivery.⁶

"Abbott is leading the way in helping doctors manage common arrhythmias with the most holistic portfolio for this condition in the world," said Christopher Piorkowski, M.D., chief medical officer of Abbott's electrophysiology business. "The EnSite X EP System is unmatched in determining the exact location where ablation is required. Coupled with the TactiFlex catheter, patients can now feel even more confident that their procedure will deliver safe and effective results."

The Abbott TactiFlex catheter generated strong clinical outcomes in the [TactiFlex AF IDE study](#)⁷. The study showed the catheter created fast, safe lesions to treat AFib with over 99% acute procedural success.¹

The TactiFlex catheter is also approved for use in Europe, Japan, Africa and Australia.

For U.S. important safety information on Abbott's [TactiFlex™ Ablation Catheter, Sensor Enabled™](#), visit: <https://www.cardiovascular.abbott/us/en/hcp/products/electrophysiology/ablation-technology/tactiflex-se-ablation-catheter/indications-safety-warnings.html>.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott/, on Facebook at www.facebook.com/Abbott and on Twitter [@AbbottNews](https://twitter.com/AbbottNews).

¹ CL1017540 TactiFlex PAF IDE PMA Report

² Lo MY, Sanders P, Sommer P, Kalman JM, Siddiqui UR, Sundaram S, Piorkowski C, Olson N, Madej SM, Gibson DN. Safety and effectiveness of a next-generation contact force catheter: results of the TactiSense trial. Clinical Electrophysiology. 2021 Aug 1;7(8):1013-21.

³ Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. *Int J Stroke*. 2021 Feb;16(2):217-221. doi: 10.1177/1747493019897870. Epub 2020 Jan 19. Erratum in: *Int J Stroke*. 2020 Jan 28;:1747493020905964. PMID: 31955707.

⁴ Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. *J Geriatr Cardiol*. 2017 Mar;14(3):195-203. doi: 10.11909/j.issn.1671-5411.2017.03.011. PMID: 28592963; PMCID: PMC5460066.

⁵ Go AS, Hylek EM, Phillips KA, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285(18):2370-2375. doi:10.1001/jama.285.18.2370

⁶ Compared to conventional 56-hole catheters. Ambrosius Nick, Fish Jeffrey, & Tranter John. Flexible, Kerfed Ablation Catheter Tip Provides Superior Stability in a Bench Model APHRS 2018: Abstract Book; 2018, October 17-18; Taipei, Taiwan. Abstract nr 1170.

⁷ CL1019990 TactiFlex PAF IDE As Treated Repeat Procedure Details

SOURCE Abbott

For further information: Abbott Media: Shelley Lange (612) 346-3514; Abbott Financial: Michael Comilla (224) 668-1872

Additional assets available online:

